Litcius/Paper detail

TIGIT/CD155 blockade enhances anti-PD-L1 therapy in head and neck squamous cell carcinoma by targeting myeloid-derived suppressor cells

Liang Mao, Yao Xiao, Qi‐Chao Yang, Shao‐Chen Yang, Leilei Yang, Zhi‐Jun Sun

2021Oral Oncology63 citationsDOI

Topics & Concepts

TIGITHead and neck squamous-cell carcinomaCancer researchTumor microenvironmentMyeloid-derived Suppressor CellPD-L1Immune systemMedicineDownregulation and upregulationImmunologyT cellImmunotherapyCancerBiologyInternal medicineHead and neck cancerSuppressorBiochemistryGeneImmune cells in cancerAcute Myeloid Leukemia ResearchCancer Immunotherapy and Biomarkers
TIGIT/CD155 blockade enhances anti-PD-L1 therapy in head and neck squamous cell carcinoma by targeting myeloid-derived suppressor cells | Litcius